Department of Cellular and Molecular Medicine, Division of Clinical Sciences, St George's University of London, London, UK.
Steroids. 2010 Dec 12;75(13-14):1082-8. doi: 10.1016/j.steroids.2010.07.007. Epub 2010 Jul 21.
It has been previously demonstrated that 1,25 dihydroxyvitamin D(3) (1,25-D(3)) exerts inhibitory effects in breast cancer cells. The aim of this study was to determine whether mitogen-activated protein kinase (MAPK) pathways are associated with 1,25-D(3)-induced cell death in breast cancer. We used three breast cell lines which have different sensitivities to 1,25-D(3) treatment. Non-malignant MCF-12A cells were more sensitive to 1,25-D(3) treatment than malignant MCF-7 cells (growth inhibition IC(50) 75 nM vs. 100 nM, p<0.001) while malignant MDA-MB-231 cells were resistant. Moreover, 1,25-D(3)-induced apoptosis was caspase-dependent in MCF-12A cells and caspase-independent in MCF-7 cells. Following MAPK activation analysis, we found a significant activation of JNK in MCF-12A cells and malignant MCF-7 cells in response to 1,25-D(3) treatment. Furthermore, 1,25-D(3) treatment stimulated p38 activity in MCF-12A cells and in MCF-7 cells. ERK1/2 activity was unaffected by 1,25-D(3) treatment in all breast cells. Importantly, no increased MAPK activity was observed in MDA-MB-231 breast cancer cells which displayed resistance to 1,25-D(3)-induced apoptosis. Utilising specific pharmacological inhibitors of JNK and p38, it was demonstrated that MCF-12A and MCF-7 cells were protected from death induced by 1,25-D(3). These results implicate JNK and p38 signalling in 1,25-D(3)-induced cancer breast cell death.
先前已经证明 1,25 二羟维生素 D(3)(1,25-D(3))对乳腺癌细胞具有抑制作用。本研究旨在确定丝裂原活化蛋白激酶(MAPK)途径是否与 1,25-D(3)诱导的乳腺癌细胞死亡有关。我们使用了三种对 1,25-D(3)处理具有不同敏感性的乳腺癌细胞系。非恶性 MCF-12A 细胞比恶性 MCF-7 细胞对 1,25-D(3)处理更敏感(生长抑制 IC(50)为 75 nM 对 100 nM,p<0.001),而恶性 MDA-MB-231 细胞则具有抗性。此外,1,25-D(3)诱导的 MCF-12A 细胞凋亡依赖于半胱天冬酶,而 MCF-7 细胞凋亡不依赖于半胱天冬酶。在进行 MAPK 激活分析后,我们发现 MCF-12A 细胞和恶性 MCF-7 细胞在 1,25-D(3)处理后 JNK 显著激活。此外,1,25-D(3)处理刺激 MCF-12A 细胞和 MCF-7 细胞中 p38 的活性。在所有乳腺癌细胞中,ERK1/2 活性不受 1,25-D(3)处理的影响。重要的是,在对 1,25-D(3)诱导的凋亡具有抗性的 MDA-MB-231 乳腺癌细胞中未观察到 MAPK 活性增加。利用 JNK 和 p38 的特异性药理抑制剂,证实 MCF-12A 和 MCF-7 细胞免受 1,25-D(3)诱导的死亡。这些结果表明 JNK 和 p38 信号通路参与了 1,25-D(3)诱导的乳腺癌细胞死亡。